Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06781359 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study on Plasmablastic Lymphoma Patients

Study acronym: FIL_PlaLy
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 8 of 23 sitesv4
  2. Site details revised at 6 of 23 sitesv3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 1, 2025 to Feb 14, 2025
    • Site details revised at 23 of 23 sites
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an observational, multicenter, international and retrospective study, that aims to collect data on clinical and pathological characteristics, treatment regimens, outcome, and prognostic factors (clinical, biomarkers and/or radio-metabolic) in patients affected by PBL.
Trial Details
NCT Number NCT06781359
Lead Sponsor Fondazione Italiana Linfomi - ETS
Collaborators: AIL Roma - Italia, AIL Cuneo - Italia
Conditions
(from sponsor)		 Plasmablastic Lymphoma
Related terms Plasmablastic Lymphoma
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov